Nanocarrier-based miRNA delivery strategies demonstrate significant potential in the treatment of OA

The gap

Evidence profile

Sourced from the future work of the source papers, classified as general, drawn from work published between 2025 and 2026, spanning 4 journals. Those papers have been cited 23 times in total.

Supporting evidence — 4 representative gaps

• Smart Nanocarrier Systems for Diabetic Wound Healing: Preclinical Innovations and Clinical Progress in Drug and Gene Delivery (2026) · Journal of Drug Delivery and Therapeutics · cited 1× · doi

  chronic inflammation, Diabetic wounds represent one of the most challenging manifestations of metabolic disease, arising from the convergence of impaired angiogenesis, oxidative stress, neuropathy, infection and extracellular matrix dysfunction. Traditional therapeutic strategies-largely focused on symptom management or single-target interventions—have proven insufficient to address the multifactorial and dynamic nature of these wounds. As synthesized this review, nanocarrier-mediated drug delivery systems offer a spatially, transformative paradigm by temporally therapeutic intervention. and molecularly precise throughout enabling 10.1 Key Advances Highlighted in This Review This review highlights several transformative advances that are redefining the management of diabetic wounds. Nanocarrier platforms have shifted the therapeutic paradigm from single-agent interventions to systems- level approaches, integrating herbal, synthetic, semi- synthetic and gene-based therapeutics to simultaneously modulate inflammation, angiogenesis, infection and tissue regeneration. Modern nanomaterials contribute beyond passive delivery by actively shaping wound biology through intrinsic antimicrobial activity, redox modulation, immune regulation and support of extracellular matrix remodeling. At the molecular level, gene-based payloads, miRNAs, and siRNAs delivered via non-viral nanocarriers offer precise control over dysregulated signaling networks, enabling pathway addressing reprogramming downstream deficits. Importantly, emerging strategies emphasize the heterogeneity of diabetic wounds, advocating for disorder-specific and phase-aware designs that tailor interventions to wound subtype and healing stage, thereby maximizing therapeutic efficacy and advancing personalized regenerative medicine. simply rather than 10.2 Persistent Challenges Limiting Clinical

  generalfuture work
  Keywords: wounds therapeutic diabetic interventions review inflammation angiogenesis infection extracellular matrix strategies management single nanocarrier delivery
• Nanotechnology in Cancer Immunotherapy (2026) · International Journal of Creative and Open Research in Engineering and Management · doi

  Future research is focused on personalized nanomedicine, smart nanoparticles, theranostic systems, and advanced nano-vaccines. Continued development in this field may lead to safer, more effective, and patient- specific cancer therapies. © 2026 The Author(s). Published by IJCOPE Journal. Website: https://ijcope.org/ 3 International Journal of Creative and Open Research in Engineering and Management ISSN: 3108-1754 (Online) Volume 02 Issue 05 May-2026 | Impact Factor: 3.5

  generalfuture work
  Keywords: ijcope journal future focused personalized nanomedicine smart nanoparticles theranostic systems advanced nano vaccines continued development
• Current status and future prospects of nanocarrier-mediated miRNA delivery for osteoarthritis therapy (2026) · Frontiers in Medicine · cited 5× · doi

  Nanocarrier-based miRNA delivery strategies demonstrate significant potential in the treatment of OA, yet several critical research gaps remain to be addressed. Future studies should delve into material safety, disease heterogeneity, and clinical translational feasibility, striving to develop novel smart delivery systems. First, biosafety assessment remains one of the most significant research gaps. Future efforts should establish a long-term, comprehensive safety evaluation system and develop novel materials with enhanced

  generalfuture work
  Keywords: delivery significant gaps future safety develop novel nanocarrier based mirna strategies demonstrate potential treatment several
• Integration of MicroRNAs with nanomedicine: tumor targeting and therapeutic approaches (2025) · Frontiers in Cell and Developmental Biology · cited 17× · doi

  The integration of microRNA-based therapies with nanomedicine represents a groundbreaking approach in the field of cancer treatment. Nanoparticles, serving as efficient delivery systems, offer a means to enhance the stability, bioavailability, and targeting of miRNAs, making it possible to restore tumor-suppressive miRNAs or inhibit oncogenic miRNAs with high precision. This innovative combination traditional holds the potential cancer therapies and offer more precise, personalized, and effective treatments for cancer patients. to overcome the limitations of While significant challenges remain, particularly in the areas of immunogenicity, toxicity, and off-target effects, recent advances in nanoparticle design and targeting strategies have paved the way for the clinical application of miRNA-based nanomedicine. These challenges are being addressed through the development of smart Frontiers in Cell and Developmental Biology 10 frontiersin.org Telkoparan-Akillilar et al. 10.3389/fcell.2025.1569101 nanoparticles, biodegradable materials, and personalized treatment strategies, which hold great promise for improving the therapeutic index of miRNA-based therapies. the synergistic combination Additionally, of miRNA therapies with other treatment modalities such as chemotherapy, radiotherapy, and immunotherapy has shown substantial promise in preclinical and early clinical trials. This approach could revolutionize cancer treatment by enhancing the therapeutic effects while minimizing side effects, thus offering a comprehensive and integrated solution to the complex nature of cancer. Looking ahead, continued research and development in the areas of nanoparticle formulations, miRNA delivery optimization, and overcoming safety and efficacy challenges will be crucial to translating miRNA-nanomedicine into a routine clinical practice. With ongoing advancements, the integration of miRNA-based therapies with nanomedicine has the potential to become a cornerstone in personalized cancer treatment, offering new hope to patients and significantly improving treatment outcomes worldwide.

  generalfuture work
  Keywords: cancer treatment mirna therapies based nanomedicine mirnas personalized challenges effects clinical integration approach nanoparticles delivery

Questions about this gap